Developer docs
API playgroundTry for free, no card

Search company profiles

HanchorBio

Full company profile

uuid0000nd2

Namestring
HanchorBio
Legal namestring
HanchorBio Inc.
Websiteurl
hanchorbio.com
Company typeenum
Public
Founded yearint
2020
Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, fusion protein biologics, antibody drug development, clinical-stage biopharmaceutical, cancer immunotherapy pipeline
Industry2 codes
PRIMARYHLAAAAAD
Fusion Proteins & Fc-Engineered Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-Oncology Biologics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

HanchorBio generates revenue through out-licensing of its clinical-stage drug candidates to global pharmaceutical partners. The company received an upfront payment from the HCB101 licensing agreement with Henlius valued at up to US$202 million (including upfront, development, regulatory, and commercial milestones). The company reported 2025 revenue of NT$312 million from this first licensing deal, representing its first licensing revenue. Future revenue is expected to come from additional licensing deals, milestone payments, and royalty streams as programs advance through clinical development and commercialization.

hanchorbio.com
2Government Grants and Subsidies
TypeLicensing Royalties
Description

The company receives support from government programs for R&D activities, including Taiwan's biotechnology development incentives. 2024 R&D investment totaled NT$789 million.

hanchorbio.com
3IPO Proceeds and Capital Markets
TypeLicensing Royalties
Description

HanchorBio completed its IPO on the Taiwan Innovation Board in May 2026, raising NT$680 million in a pre-listing capital increase in September 2025, with the IPO issuing 9.4 million new shares at NT$120 per share. Post-IPO, the company holds approximately US$140 million in cash and available bank credit facilities.

hanchorbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1No commercialized products; company in clinical development stage
ModelOtherBilling cadenceOther
Notes

HCB101 is in Phase 1/1b/2a clinical trials; no approved commercial products exist yet. Pricing details not applicable as the company generates revenue through licensing deals, milestones, and capital markets rather than product sales.

hanchorbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

HanchorBio is a clinical-stage biopharmaceutical company developing next-generation multi-functional fusion protein immunotherapies using its proprietary FBDB™ (Fc-Based Designer Biologics) platform. The company advances a pipeline of clinical and preclinical candidates — including the CD47-SIRPα inhibitor HCB101 and the tri-specific HCB301 — targeting oncology and autoimmune diseases, and generates revenue primarily by out-licensing clinical-stage assets and milestones to global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 80% objective response rate (ORR) in Phase 2a mid-dose cohort for second-line gastric cancer (HCB101 + ramucirumab + paclitaxel), vs. 26.5% historical ORR for standard-of-care ramucirumab + paclitaxel alone
+7 more records
Product and service4 records
1HCB101 — SIRPα–IgG4 Fc Fusion Protein (CD47-SIRPα inhibitor)
CategoryImmuno-oncology biologic (CD47-SIRPα inhibitor)
Description

Investigational biologic designed via AlphaFold-guided structural modeling to block the CD47-SIRPα innate immune checkpoint while minimizing red blood cell binding, delivering a cytopenia-sparing safety profile and >99% CD47 receptor occupancy at therapeutic doses. Developed for advanced solid tumors (gastric, head and neck, colorectal, triple-negative breast cancer) as a combination backbone; licensed to Henlius for mainland China and certain territories.

2HCB301 — Tri-specific SIRPα–PD-L1–TGF-β Fusion Protein
CategoryImmuno-oncology biologic (tri-specific fusion protein)
Description

First-in-class investigational tri-specific fusion protein designed to simultaneously modulate the CD47/SIRPα, PD-L1/PD-1, and TGF-β/TGFβ-R pathways within a single molecule for immune-resistant solid tumors.

3HCB206 — Dual-Target SIRPα–CD20 Fusion Protein
CategoryAutoimmune / oncology biologic (dual-target fusion protein)
Description

Investigational dual-target fusion protein combining targeted B-cell depletion with engineered innate immune (CD47-SIRPα) mechanism, designed to minimize hematologic effects; preclinical data show approximately 6-fold greater clearance of pathogenic B cells vs. competitors while remaining minimally active in healthy cells. Developed for B-cell-driven autoimmune diseases (e.g., SLE) and oncology.

4FBDB™ Platform — Fc-Based Designer Biologics
CategoryBiologics engineering platform / R&D technology
Description

Proprietary modular Fc-based scaffold engineering platform integrating AI-guided structural design (AlphaFold) for rational engineering of multi-functional fusion proteins targeting innate and adaptive immune pathways. Licensed to enable differentiated antibody therapeutics in oncology and autoimmune diseases.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Institute of Tsinghua University, Hebei
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

HanchorBio launched a research collaboration with the Institute of Tsinghua University, Hebei, to characterize the antitumor mechanisms and translational biology of HCB101. The collaboration focuses on in vivo studies spanning tumor immunity, immune cell function, antigen presentation, macrophage-mediated phagocytosis, downstream immune signaling, and hematologic biology, strengthening the scientific foundation for HCB101 development.

hanchorbio.com
2National Yang Ming Chiao Tung University (NYCU)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

HanchorBio entered a research collaboration with NYCU's College of Engineering Bioscience to advance AI-enabled biologics discovery. The collaboration integrates generative AI with experimental validation to improve speed and efficiency of early-stage candidate design and evaluation. NYCU's Drug Design and Systems Biology Laboratory (led by Prof. Jinn-Moon Yang) contributes AI model development, sequence prediction, and computational analysis capabilities, combined with HanchorBio's biologics engineering and translational validation.

hanchorbio.com
3Bloomberg (Bloomberg Intelligence)
Strategic tierMinorTypeOthersAnnounced on2026-04-24
Description

HanchorBio selected Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard, to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities. The partnership extends the company's intelligence-driven approach from molecule design to broader portfolio and market strategy.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-26
Description

HanchorBio entered a strategic partnership with WuXi Biologics (2269.HK), a leading global CRDMO, for end-to-end biologics development and manufacturing services. WuXi Biologics provides integrated services including cell line development, process development, bioassay development, drug product formulation, and GMP manufacturing for HanchorBio's next-generation bi- and multi-functional fusion protein programs. The partnership leverages WuXi Biologics' established capabilities in complex biologics (supporting 945 integrated platform projects as of 2025) to accelerate clinical translation, enhance CMC execution efficiency, and support scalable global development of HanchorBio's FBDB™ platform-derived immunotherapy portfolio.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage IO company with multiple modality programs including bispecifics. Comparable clinical-stage IO portfolio strategy with licensing optionality for individual programs.

TypeEmerging player
Description

Clinical-stage biotech developing conditionally-activated multi-specific IO biologics (PREDATOR platform). Comparable engineered multi-functional biologic platform for oncology, though smaller and INDUCER-conditioned.

TypeDirect peer
Description

Clinical-stage biotech developing CD47/SIRPα pathway inhibitors (e.g., evorpacept). Most direct competitor to HCB101 with overlapping mechanism and oncology indications; comparable clinical-stage positioning and licensing-focused BD strategy.

4Arch Oncology
TypeDirect peer
Description

Private clinical-stage biotech developing anti-CD47 antibodies for oncology. Directly comparable CD47-targeting mechanism and hematologic-toxicity differentiation strategy.

TypeDirect peer
Description

Pioneer in CD47/SIRPα therapeutics (TTI-621, TTI-622), acquired by Pfizer in 2021 for ~US$2.2B. Closest historical comparable for HanchorBio's CD47 strategy and validates Big Pharma appetite for the target.

TypeDirect peer
Description

China-based biotech commercializing bispecific antibodies (e.g., ivonescimab PD-1/VEGF). Closest Asian comparable on multi-functional biologics design and licensing-driven growth model.

TypeBroad incumbent
Description

Established Chinese biologics company with commercial PD-1 (sintilimab) and broad IO pipeline. Comparable Asian biologics developer at scale, although far broader and later-stage than HanchorBio.

TypeDirect peer
Description

Chinese biotech commercializing novel antibody therapeutics including fusion proteins (telitacicept, a TACI-Fc fusion). Directly comparable on Asia-originated fusion protein platform and licensing partnerships.

TypeDirect peer
Description

Clinical-stage IO biotech developing bispecific antibodies (e.g., CTX-009 DR5/VEGF). Comparable multi-specific antibody platform with oncology focus and similar clinical-stage positioning.

10Sino Biopharmaceutical Limited
TypeBroad incumbent
Description

Major Chinese pharmaceutical conglomerate and existing HanchorBio Series A lead investor. Comparable Asian pharma exposure and potential downstream partner, though vastly larger and more diversified.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HanchorBio

Immuno-Oncology Biologicshanchorbio.com

HanchorBio firmographics

Firmographics
Name
HanchorBio
Legal name
HanchorBio Inc.
Website
https://hanchorbio.com
Company type
Public
Founded year
2020
Operating status
Ipo
Headcount range
51–100 employees
Ownership category
akta.pro rank

HanchorBio industry classification

Industry
Product category
Immuno-Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAD
Fusion Proteins & Fc-Engineered Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Immuno-oncology therapeutics
  • Fusion protein biologics
  • Antibody drug development
  • Clinical-stage biopharmaceutical
  • Cancer immunotherapy pipeline

Where HanchorBio is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices3 records

Markets served

HanchorBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: HanchorBio generates revenue through out-licensing of its clinical-stage drug candidates to global pharmaceutical partners. The company received an upfront payment from the HCB101 licensing agreement with Henlius valued at up to US$202 million (including upfront, development, regulatory, and commercial milestones). The company reported 2025 revenue of NT$312 million from this first licensing deal, representing its first licensing revenue. Future revenue is expected to come from additional licensing deals, milestone payments, and royalty streams as programs advance through clinical development and commercialization.
  2. Government Grants and Subsidies: The company receives support from government programs for R&D activities, including Taiwan's biotechnology development incentives. 2024 R&D investment totaled NT$789 million.
  3. IPO Proceeds and Capital Markets: HanchorBio completed its IPO on the Taiwan Innovation Board in May 2026, raising NT$680 million in a pre-listing capital increase in September 2025, with the IPO issuing 9.4 million new shares at NT$120 per share. Post-IPO, the company holds approximately US$140 million in cash and available bank credit facilities.

Pricing tiers

ModelBillingPrice
OtherOtherNo commercialized products; company in clinical development stage

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

HanchorBio product offering

Product offering

Core offering

HanchorBio is a clinical-stage biopharmaceutical company developing next-generation multi-functional fusion protein immunotherapies using its proprietary FBDB™ (Fc-Based Designer Biologics) platform. The company advances a pipeline of clinical and preclinical candidates — including the CD47-SIRPα inhibitor HCB101 and the tri-specific HCB301 — targeting oncology and autoimmune diseases, and generates revenue primarily by out-licensing clinical-stage assets and milestones to global pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • HCB101 — SIRPα–IgG4 Fc Fusion Protein (CD47-SIRPα inhibitor) Investigational biologic designed via AlphaFold-guided structural modeling to block the CD47-SIRPα innate immune checkpoint while minimizing red blood cell binding, delivering a cytopenia-sparing safety profile and >99% CD47 receptor occupancy at therapeutic doses. Developed for advanced solid tumors (gastric, head and neck, colorectal, triple-negative breast cancer) as a combination backbone; licensed to Henlius for mainland China and certain territories.
  • HCB301 — Tri-specific SIRPα–PD-L1–TGF-β Fusion Protein First-in-class investigational tri-specific fusion protein designed to simultaneously modulate the CD47/SIRPα, PD-L1/PD-1, and TGF-β/TGFβ-R pathways within a single molecule for immune-resistant solid tumors.
  • HCB206 — Dual-Target SIRPα–CD20 Fusion Protein Investigational dual-target fusion protein combining targeted B-cell depletion with engineered innate immune (CD47-SIRPα) mechanism, designed to minimize hematologic effects; preclinical data show approximately 6-fold greater clearance of pathogenic B cells vs. competitors while remaining minimally active in healthy cells. Developed for B-cell-driven autoimmune diseases (e.g., SLE) and oncology.
  • FBDB™ Platform — Fc-Based Designer Biologics Proprietary modular Fc-based scaffold engineering platform integrating AI-guided structural design (AlphaFold) for rational engineering of multi-functional fusion proteins targeting innate and adaptive immune pathways. Licensed to enable differentiated antibody therapeutics in oncology and autoimmune diseases.

Quantifiable outcome

  • 80% objective response rate (ORR) in Phase 2a mid-dose cohort for second-line gastric cancer (HCB101 + ramucirumab + paclitaxel), vs. 26.5% historical ORR for standard-of-care ramucirumab + paclitaxel alone
  • +7 more outcomes

Companies that use HanchorBio

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

HanchorBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

HanchorBio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Institute of Tsinghua University, HebeiminorStrategic or Co-development Partner · 5 May 2026HanchorBio launched a research collaboration with the Institute of Tsinghua University, Hebei, to characterize the antitumor mechanisms and translational biology of HCB101. The collaboration focuses on in vivo studies spanning tumor immunity, immune cell function, antigen presentation, macrophage-mediated phagocytosis, downstream immune signaling, and hematologic biology, strengthening the scientific foundation for HCB101 development.
  • National Yang Ming Chiao Tung University (NYCU)minorStrategic or Co-development Partner · 29 April 2026HanchorBio entered a research collaboration with NYCU's College of Engineering Bioscience to advance AI-enabled biologics discovery. The collaboration integrates generative AI with experimental validation to improve speed and efficiency of early-stage candidate design and evaluation. NYCU's Drug Design and Systems Biology Laboratory (led by Prof. Jinn-Moon Yang) contributes AI model development, sequence prediction, and computational analysis capabilities, combined with HanchorBio's biologics engineering and translational validation.
  • Bloomberg (Bloomberg Intelligence)minorOthers · 24 April 2026HanchorBio selected Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard, to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities. The partnership extends the company's intelligence-driven approach from molecule design to broader portfolio and market strategy.
  • WuXi BiologicscoreStrategic or Co-development Partner · 26 January 2026HanchorBio entered a strategic partnership with WuXi Biologics (2269.HK), a leading global CRDMO, for end-to-end biologics development and manufacturing services. WuXi Biologics provides integrated services including cell line development, process development, bioassay development, drug product formulation, and GMP manufacturing for HanchorBio's next-generation bi- and multi-functional fusion protein programs. The partnership leverages WuXi Biologics' established capabilities in complex biologics (supporting 945 integrated platform projects as of 2025) to accelerate clinical translation, enhance CMC execution efficiency, and support scalable global development of HanchorBio's FBDB™ platform-derived immunotherapy portfolio.

Scale indicators12 records

Recent moves10 records

Expansion highlights5 records

HanchorBio competitors and assessment

Company assessment

Emerging players

  • Cullinan Oncology: Clinical-stage IO company with multiple modality programs including bispecifics. Comparable clinical-stage IO portfolio strategy with licensing optionality for individual programs.
  • Werewolf Therapeutics: Clinical-stage biotech developing conditionally-activated multi-specific IO biologics (PREDATOR platform). Comparable engineered multi-functional biologic platform for oncology, though smaller and INDUCER-conditioned.

Direct peers

  • ALX Oncology Holdings: Clinical-stage biotech developing CD47/SIRPα pathway inhibitors (e.g., evorpacept). Most direct competitor to HCB101 with overlapping mechanism and oncology indications; comparable clinical-stage positioning and licensing-focused BD strategy.
  • Arch Oncology: Private clinical-stage biotech developing anti-CD47 antibodies for oncology. Directly comparable CD47-targeting mechanism and hematologic-toxicity differentiation strategy.
  • Trillium Therapeutics: Pioneer in CD47/SIRPα therapeutics (TTI-621, TTI-622), acquired by Pfizer in 2021 for ~US$2.2B. Closest historical comparable for HanchorBio's CD47 strategy and validates Big Pharma appetite for the target.
  • Akeso, Inc. China-based biotech commercializing bispecific antibodies (e.g., ivonescimab PD-1/VEGF). Closest Asian comparable on multi-functional biologics design and licensing-driven growth model.
  • RemeGen Co., Ltd. Chinese biotech commercializing novel antibody therapeutics including fusion proteins (telitacicept, a TACI-Fc fusion). Directly comparable on Asia-originated fusion protein platform and licensing partnerships.
  • Compass Therapeutics: Clinical-stage IO biotech developing bispecific antibodies (e.g., CTX-009 DR5/VEGF). Comparable multi-specific antibody platform with oncology focus and similar clinical-stage positioning.

Broad incumbents

  • Innovent Biologics: Established Chinese biologics company with commercial PD-1 (sintilimab) and broad IO pipeline. Comparable Asian biologics developer at scale, although far broader and later-stage than HanchorBio.
  • Sino Biopharmaceutical Limited: Major Chinese pharmaceutical conglomerate and existing HanchorBio Series A lead investor. Comparable Asian pharma exposure and potential downstream partner, though vastly larger and more diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

HanchorBio social profiles

Digital presence

HanchorBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HanchorBio leadership team

Management profile

Number of profiles

Profiles11 records

HanchorBio subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

HanchorBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HanchorBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HanchorBio

What does HanchorBio do?

HanchorBio is a clinical-stage biopharmaceutical company developing next-generation multi-functional fusion protein immunotherapies using its proprietary FBDB™ (Fc-Based Designer Biologics) platform. The company advances a pipeline of clinical and preclinical candidates — including the CD47-SIRPα inhibitor HCB101 and the tri-specific HCB301 — targeting oncology and autoimmune diseases, and generates revenue primarily by out-licensing clinical-stage assets and milestones to global pharmaceutical partners.

Is HanchorBio a public or private company?

HanchorBio is a public company. It is currently ipo.

When was HanchorBio founded?

HanchorBio was founded in 2020. It employs 51 to 100 people.

Where is HanchorBio based?

HanchorBio is headquartered in Taipei, Taiwan, in the Asia region.

How does HanchorBio make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are government Grants and Subsidies and IPO Proceeds and Capital Markets.

Who are HanchorBio's main competitors?

Emerging players on record are Cullinan Oncology and Werewolf Therapeutics. Direct peers are ALX Oncology Holdings, Arch Oncology, Trillium Therapeutics, Akeso, Inc., RemeGen Co., Ltd. and Compass Therapeutics. Broad incumbents are Innovent Biologics and Sino Biopharmaceutical Limited.

Does HanchorBio have an API?

No public API is recorded for HanchorBio.

What industry is HanchorBio in?

HanchorBio's product category is Immuno-Oncology Biologics. Its primary akta.pro industry code is HLAAAAAD, Fusion Proteins & Fc-Engineered Biologics, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACHanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine CombinationsHanchorBio and Aston Sci announced a collaboration to evaluate HCB101 macrophage-directed immunotherapy with Aston Sci's AST-301 HER2 vaccine and a PD-L1 vaccine. Both candidates have U.S. FDA Orphan Drug Designation for gastric cancer. The partnership aims to create a continuous immune loop for durable tumor suppression.PR NewswireHanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine CombinationsHanchorBio and Aston Sci announced a strategic collaboration to combine HCB101, a macrophage-directed immunotherapy, with AST-301, a HER2-directed DNA vaccine in Phase 2. Both assets have FDA Orphan Drug Designations for gastric cancer, and initial studies target gastric and breast cancers. The partnership will also explore combinations with an investigational PD-L1 vaccine.TradingViewHanchorBio, Inc. Signs MOU With Aston Sci to Test HCB101 With Cancer VaccinesHanchorBio signed an MOU with Aston Sci to evaluate HCB101 combined with AST-301, a Phase 2 HER2 DNA vaccine, and an investigational PD-L1 vaccine. Both assets hold FDA Orphan Drug Designation for gastric cancer, and the partnership targets HER2+ solid tumors.MorningstarHanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical BenefitHanchorBio announced the FDA cleared its HCB101 Single-Patient Expanded Access Protocol, allowing a Phase 1 patient to continue treatment. The determination applies only to this individual patient and does not constitute approval of HCB101. The company says this is the first reported U.S. Expanded Access case for a SIRPα-Fc fusion protein.PR NewswireHanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical BenefitHanchorBio announced the FDA cleared its HCB101 Single-Patient Expanded Access Protocol, allowing a Phase 1 patient to continue treatment. The company says this is the first U.S. Expanded Access case for a SIRPα-Fc fusion protein. The determination applies only to this protocol and does not constitute approval of HCB101.GurufocusHanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led byHanchorBio (TWSE: 7827), a global clinical-stage biotechnology company, announced a strategic collaboration through a memorandum of understanding with Professor Sung-Liang Yu's research team at National Taiwan University, a key participant in the Taiwan Cancer Moonshot Program. The partnership combines TCMP's cancer multi-omics and translational research capabilities with HanchorBio's FBDB™ (Fc-Based Designer Biologics) immuno-oncology platform to accelerate biomarker-driven immunotherapy development and improve precision in clinical development strategies. This collaboration aims to establish a translational model connecting patient-derived molecular insights to biomarker-guided clinical development for next-generation precision immunotherapies.AijournHanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision OncologyHanchorBio announced a strategic collaboration with Professor Sung-Liang Yu's team from National Taiwan University to advance precision oncology and immunotherapy. The partnership leverages Taiwan Cancer Moonshot Program's multi-omics research to support biomarker-driven drug development and improve clinical trial strategies.TradingViewHanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision OncologyHanchorBio has entered into a strategic collaboration with the Taiwan Cancer Moonshot Project-NTU Subteam, led by Professor Sung-Liang Yu at National Taiwan University, to advance precision oncology research. The partnership aims to integrate the subteam's cancer multi-omics capabilities with HanchorBio's clinical-stage immuno-oncology platform to accelerate biomarker-driven drug development and improve patient selection strategies.GurufocusHanchorBio Tests Broader Ambitions for HCB101 Through InxMed ParHanchorBio, Inc. (TWSE: 7827) has signed a strategic memorandum of understanding with InxMed (Shanghai) Co., Ltd. to conduct preclinical and translational research combining HCB101 (HanchorBio's SIRPα-Fc fusion protein targeting the CD47/SIRPα pathway) with InxMed's investigational assets including IN10018/ifebemtinib and OMTX705. No licensing economics, upfront payment, or clinical trial commitment has been disclosed, positioning this as a strategic exploration rather than a financial milestone. The collaboration tests whether HCB101's macrophage-centered immune activation approach can be paired with drugs addressing tumor physical and biological defenses for difficult-to-treat solid tumors.AijournHanchorBio Tests Broader Ambitions for HCB101 Through InxMed PartnershipHanchorBio, a Taiwan-listed clinical-stage biotech, has signed a strategic memorandum of understanding with InxMed (Shanghai) through its subsidiary FBD Biologics to conduct preclinical and translational research combining HCB101 with InxMed's investigational oncology assets, including the FAK inhibitor IN10018/ifebemtinib and the FAP-targeted ADC OMTX705. The partnership aims to test whether HCB101, a SIRP\u03b1-Fc fusion protein currently in clinical development for gastric cancer, can expand beyond its anchor indication to become a broader combination therapy for difficult-to-treat solid tumors. No licensing economics, upfront payments, or clinical trial commitments have been disclosed, making this a strategic exploration rather than a financial milestone.